Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cerilliant
Dow
McKesson
Farmers Insurance
McKinsey
Boehringer Ingelheim
Federal Trade Commission
Baxter

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EPIDUO FORTE

« Back to Dashboard

Clinical Trials for Epiduo Forte

Trial ID Title Status Sponsor Phase Summary
NCT00757523 Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris Completed GlaxoSmithKline Phase 4 The purpose of this study is to compare the effectiveness of two marketed products in subjects with facial acne vulgaris
NCT00757523 Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris Completed Stiefel, a GSK Company Phase 4 The purpose of this study is to compare the effectiveness of two marketed products in subjects with facial acne vulgaris
NCT00907101 Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes Completed Galderma Laboratories, L.P. Phase 4 The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing antibiotic sensitive and resistant strains of P acnes in vivo.
NCT00919191 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face Completed Valeant Pharmaceuticals International, Inc. Phase 4 A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.
NCT00952523 Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face Completed Valeant Pharmaceuticals International, Inc. Phase 4 A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.
NCT01014689 Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris Completed Galderma Phase 3 Randomized, controlled, multi-center, double-blind, parallel-group comparison study in Subjects with moderate to severe acne vulgaris on the face. The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% / Benzoyl Peroxide (BPO) 2.5% Gel associated with Lymecycline 300mg Capsules compared to Adapalene 0.1% /Benzoyl Peroxide 2.5% Vehicle Gel associated with Lymecycline 300mg Capsules, in the treatment of moderate to severe acne vulgaris. The safety of the two treatment regimens will also be evaluated.
NCT01138735 Epiduo Pediatric Acne Study Completed Galderma Phase 4 The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Epiduo Forte

Condition Name

Condition Name for Epiduo Forte
Intervention Trials
Acne Vulgaris 17
Acne 7
P Acnes Colonization 1
Microparticles 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Epiduo Forte
Intervention Trials
Acne Vulgaris 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Epiduo Forte

Trials by Country

Trials by Country for Epiduo Forte
Location Trials
United States 42
India 5
Canada 4
Germany 3
Poland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Epiduo Forte
Location Trials
Pennsylvania 4
North Carolina 4
Florida 4
Texas 4
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Epiduo Forte

Clinical Trial Phase

Clinical Trial Phase for Epiduo Forte
Clinical Trial Phase Trials
Phase 4 12
Phase 3 5
Phase 1 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Epiduo Forte
Clinical Trial Phase Trials
Completed 20
Not yet recruiting 2
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Epiduo Forte

Sponsor Name

Sponsor Name for Epiduo Forte
Sponsor Trials
Galderma 5
Galderma Laboratories, L.P. 5
Galderma Laboratorium GmbH 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Epiduo Forte
Sponsor Trials
Industry 24
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
Johnson and Johnson
Merck
Baxter
Dow
Citi
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.